Maravai Lifesciences Holdings (MRVI) Debt to Equity (2020 - 2026)
Maravai Lifesciences Holdings (MRVI) recorded quarterly Debt to Equity of $0.65 in Q1 2026, down 52.47% quarter-over-quarter from $1.37 in Q4 2025, and up 17.4% on a YoY basis from $0.56 in Q1 2025.
Maravai Lifesciences Holdings (MRVI) Debt to Equity (2020 - 2026) Analysis & Trends
Maravai Lifesciences Holdings' Debt to Equity history runs 7 years deep, the most recent figure standing at $0.65 for Q1 2026.
- In Q1 2026, Debt to Equity rose 17.4% year-over-year to $0.65; the TTM figure through Mar 2026 stood at $0.65 (up 17.4% YoY), while the FY2025 annual figure was $1.37, up 167.96% from the prior year.
- Debt to Equity was $0.65 for Q1 2026 at Maravai Lifesciences Holdings, down from $1.37 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $1.37 in Q4 2025 to a low of $0.51 in Q4 2024.
- Historically, Debt to Equity has averaged $0.72 across 5 years, with a median of $0.67 in 2024.
- The sharpest annual moves came in 2022 and 2025: Debt to Equity tumbled 56.3% in 2022, then soared 167.96% in 2025.
- A 5-year view of Debt to Equity shows it stood at $0.58 in 2022, then rose by 13.89% to $0.66 in 2023, then fell by 22.74% to $0.51 in 2024, then jumped by 167.96% to $1.37 in 2025, then plunged by 52.47% to $0.65 in 2026.
- The last three Debt to Equity figures came in at $0.65 (Q1 2026), $1.37 (Q4 2025), and $0.68 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 0.32 |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | - |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | Maravai Lifesciences Holdings | 747.50 Mn | 739.10 Mn | 33.70 Mn | 0.65 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.65 |
| Dec 31, 2025 | 1.37 |
| Sep 30, 2025 | 0.68 |
| Jun 30, 2025 | 0.63 |
| Mar 31, 2025 | 0.56 |
| Dec 31, 2024 | 0.51 |
| Sep 30, 2024 | 0.85 |
| Jun 30, 2024 | 0.68 |
| Mar 31, 2024 | 0.67 |
| Dec 31, 2023 | 0.66 |
| Sep 30, 2023 | 0.59 |
| Jun 30, 2023 | 0.59 |
| Mar 31, 2023 | 0.80 |
| Dec 31, 2022 | 0.58 |
| Sep 30, 2022 | 0.89 |
| Jun 30, 2022 | 0.68 |
| Mar 31, 2022 | 0.85 |
| Dec 31, 2021 | 1.03 |
| Sep 30, 2021 | 1.15 |
| Jun 30, 2021 | 1.56 |